ZÜRICH researchers have developed an implantable electronic device that can lower high blood sugar within an hour, a significant advance in diabetes treatment. The system, called Echo (Electrocatalytic Closed-Loop Health Optimization), works by converting excess glucose in the blood into gluconate, which is then naturally excreted by the kidneys, WELT reported.
Diabetes affects over 10% of German adults, with approximately 450,000 new cases each year. Current treatments rely on medication, lifestyle changes, and insulin injections. The ETH ZÜRICH device, led by Martin Fussenegger, offers a new approach by using electronics to directly remove glucose from the bloodstream instead of relying on the body’s insulin response or drugs. This method, which bypasses the need for living cells or enzymes, moves treatment from managing symptoms to directly controlling blood sugar levels.
How the Echo Implant Works
The Echo implant is a wirelessly powered device that operates on a simple yet sophisticated principle. At its core is a catalyst made of graphite felt coated with gold nanostructures and platinum particles. When activated, these materials facilitate an electrochemical reaction that transforms excess glucose into gluconate. The device is designed for biocompatibility and operates at a very low voltage, ensuring no tissue damage from electrical or thermal effects, as confirmed by the research team.
The system’s function is tightly controlled by a closed-loop mechanism. It connects wirelessly to a standard glucose sensor, such as those worn on the arm, which measures tissue sugar levels via Bluetooth to a smartphone or smartwatch. If glucose levels rise above a predefined threshold, the implant automatically activates, begins processing the excess sugar, and shuts down once levels return to a normal range. This automatic regulation prevents the constant presence of drugs in the body and allows for precise, on-demand treatment.
Implant Turns Sugar into Flushable Substance
- The implant is not a pill; it’s a small device placed under the skin that uses electricity to change excess sugar into a substance your body flushes out.
- It works automatically, turning on only when your blood sugar is too high and turning off when it’s normal, so you don’t need to guess or calculate doses.
- The device has only been tested in mice so far; it is not yet available for people, and clinical tests in humans are still required before it could become one.
Device Normalized Mouse Blood Sugar Quickly
The ETH ZÜRICH team first validated the Echo system in a laboratory setting, testing its performance in a five-liter glucose solution, which approximates the blood volume of an adult human. Subsequently, the device was tested on overweight mice with type-2 diabetes. The results were promising: blood sugar levels normalized within one hour of activation. Over a six-week period, the mice not only maintained stable blood sugar but also experienced significant weight loss and improved blood fat (triglyceride) levels. The device functioned reliably throughout the trial without causing hypoglycemia or other observed side effects.
This dual benefit of lowering blood sugar and reducing weight is particularly significant. It suggests that the Echo implant could address both type-2 diabetes and obesity, which in medical circles are sometimes referred to together as “diabesity”. The mice also showed improved blood fat values alongside the weight loss.
| Parameter | Observation in Mice Study |
|---|---|
| Time to Normalize Blood Sugar | Within one hour of activation |
| Duration of Testing | Six weeks |
| Effect on Weight | Significant reduction observed |
| Reported Side Effects | No hypoglycemia or tissue damage |
The Hurdles for Human Application
While the results in mice are encouraging, clinical tests in humans are still pending before the Echo implant can be considered for human use. Andreas Birkenfeld, an independent diabetologist at the University Hospital Tübingen, sees the technology as a step forward: “I find this a really exciting approach,” he told the Science Media Center Germany. He highlighted the controllability that the catalyst enables compared with classic SGLT2 inhibitors, and noted that the process works independently of insulin and would not require regular medication intake — while making clear that in type-1 diabetes it would not replace insulin.
The developers emphasize that the system operates at a very low voltage and that their experiments showed neither electrical nor thermal effects caused tissue damage.
Device Unsuitable for Type 1 Diabetics
The Echo implant is an experimental device and is not a current treatment option for diabetes. These include:
- Individuals with Type 1 Diabetes and high risk of ketoacidosis: The device removes glucose but does not replace insulin. In a state of severe insulin deficiency, the body could still produce dangerous levels of ketones, leading to a life-threatening condition called ketoacidosis.
- Patients with impaired kidney function: Since gluconate is excreted through the kidneys, individuals with pre-existing kidney disease may not be able to clear the substance effectively, potentially leading to complications.
Patients with diabetes should always consult their healthcare provider before considering any new treatment, even experimental ones.
Path to Market and Regulatory Approval
The ETH ZÜRICH team has announced its intention to develop Echo into a medical product. According to the developers, the integration of Echo with existing digital health systems is intended to accelerate the technological transition to market maturity in the coming years. Using Bluetooth to connect to smartphones and smartwatches, the system aims to be user-friendly and fit into modern diabetes management, matching the current trend of continuous glucose monitoring (CGM) and other connected health technologies. However, the system is not yet a replacement for established treatments, and it does not represent a cure.
“The actual innovation for me is not that glucose is removed from the body, but that this is electronically controlled for the first time,” explained Andreas Birkenfeld of the University Hospital Tübingen.
Funding and Future Outlook
The research behind the Echo implant was conducted by a team at ETH ZÜRICH under the leadership of Martin Fussenegger and was published in the journal Science on 22 October 2026. The explicit goal stated by the team is to transition the technology from a laboratory prototype to a viable medical product, a process that will require further development and collaboration.
Despite the excitement surrounding the Echo device, independent experts urge a measured perspective. Siegfried Ussar, director of the Adipocytes and Metabolism Department at the Helmholtz Center Munich, emphasizes the precise control: “In contrast to the unregulated inhibitor approach, this device can in theory be controlled with precision,” he explains. As a standalone therapy, however, the implant is not an option, as it does not address the underlying insulin deficiency. The technology represents a fascinating proof-of-concept, but its ultimate role in diabetes management—whether as a primary therapy, a supplemental tool, or a niche application—will only be determined by rigorous clinical trials in humans. Until then, it remains a promising but distant prospect in the fight against a widespread and challenging disease.
References
- Fussenegger, M. et al. (2026). Science.
- Birkenfeld, A. Interview with Science Media Center Germany.
- Ussar, S. Director, Adipocytes and Metabolism Department, Helmholtz Center Munich.
